Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
STS101 (dihydroergotamine nasal powder). STS101 is an investigational product which is being evaluated in phase 1 clinical trials for the acute treatment of migraine with or without aura in adults.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: STS101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
STS101 (dihydroergotamine mesylate) constricts the pain-producing intracranial extracerebral blood vessels at the 5-HT1B receptors and inhibiting the trigeminal neurotransmission at the peripheral and central 5-HT1D receptors.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: STS101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2023
Details:
The acquisition will expand SNBL's pipeline by including STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: STS101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SNBL
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 16, 2023
Details:
STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: STS101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: STS101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: STS101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
Subjects administered STS101 (dihydroergotamine mesylate) to treat their migraine attacks for as long as 18 months in a real-world setting, confirm the favorable safety and tolerability profile of STS101 observed to date in more than 1,600 clinical trial participants.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: STS101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
The co-primary endpoints of the SUMMIT trial, to be assessed at two hours after STS101 (Dihydroergotamine Mesylate) administration, are freedom from pain and freedom from most bothersome symptom (from among photophobia, phonophobia or nausea).
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: STS101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
STS101 (dihydroergotamine mesylate) is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: STS101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: STS101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022